Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.502, 2006-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Natalizumab benefits QOL in multiple sclerosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 577, 2009-01 ,pp. :
Access to resources
Recommend
Natalizumab in MS well tolerated
Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. :
Natalizumab shows clinical, cost and QOL benefits
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 514, 2006-01 ,pp. :
Rapid improvement in QOL following infliximab in RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 494, 2006-01 ,pp. :
Somatropin provides long-term QOL improvement in GHD
Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. :